Ryan Allway October 12th, 2021 Psychedelics, Top News MIAMI, Oct. 12, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is... Read more
Ryan Allway September 24th, 2021 App, Exclusive, Psychedelics, Top Story Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the... Read more
Ryan Allway September 20th, 2021 Psychedelics Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development, Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage National Presence Will Bring Psychedelic Wellness Treatment to the Masses VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ – Delic Holdings Corp (“Delic” or the “Company“)... Read more
Ryan Allway September 10th, 2021 Psychedelics BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect’s... Read more
VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has reached a commercial... Read more
Ryan Allway August 30th, 2021 Psychedelics, Top News Integrated Rehab and Performance Re-Branded as IRP Health to Better Reflect its Planned Evolution into a Multidisciplinary Business VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a... Read more
Ryan Allway June 3rd, 2021 Psychedelics VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (formerly, Myconic Capital Corp.) (“Ketamine One” or the “Company”) (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to... Read more
Ryan Allway May 25th, 2021 Psychedelics TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive... Read more
Ryan Allway April 15th, 2021 Psychedelics TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (“PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide an update on its psychedelic product programs as it relates to the clinical and commercial development of ketamine and... Read more
In recent years, the United States has seen a proliferation of ketamine clinics. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. In an even larger trend, the health care provider…